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Background: Angiogenesis, the process in which new blood vessels are formed from preexisting ones, is highly
dependent on the presence of classical angiogenic factors. Recent evidence suggests that axonal guidance proteins
and their receptors can also act as angiogenic regulators. Netrin, a family of laminin-like proteins, specifically
Netrin-1 and 4, act via DCC/Neogenin-1 and UNC5 class of receptors to promote or inhibit angiogenesis,
depending on the physiological context.
Methods: Mesenchymal stem cells secrete a broad set of classical angiogenic factors. However, little is known
about the expression of non-canonical angiogenic factors such as Netrin-1. The aim was to characterize the
possible secretion of Netrin ligands by Wharton’s jelly-derived mesenchymal stem cells (WJ-MSC). We evaluated if
Netrin-1 presence in the conditioned media from these cells was capable of inducing angiogenesis both in vitro
and in vivo, using human umbilical vein endothelial cells (HUVEC) and chicken chorioallantoic membrane (CAM),
respectively. In addition, we investigated if the RhoA/ROCK pathway is responsible for the integration of Netrin
signaling to control vessel formation.
Results: The paracrine angiogenic effect of the WJ-MSC-conditioned media is mediated at least in part by Netrin-1
given that pharmacological blockage of Netrin-1 in WJ-MSC resulted in diminished angiogenesis on HUVEC. When
HUVEC were stimulated with exogenous Netrin-1 assayed at physiological concentrations (10–200 ng/mL),
endothelial vascular migration occurred in a concentration-dependent manner. In line with our determination of
Netrin-1 present in WJ-MSC-conditioned media we were able to obtain endothelial tubule formation even in the
pg/mL range. Through CAM assays we validated that WJ-MSC-secreted Netrin-1 promotes an increased
angiogenesis in vivo. Netrin-1, secreted by WJ-MSC, might mediate its angiogenic effect through specific cell
surface receptors on the endothelium, such as UNC5b and/or integrin α6β1, expressed in HUVEC. However, the
angiogenic response of Netrin-1 seems not to be mediated through the RhoA/ROCK pathway.
Conclusions: Thus, here we show that stromal production of Netrin-1 is a critical component of the vascular
regulatory machinery. This signaling event may have deep implications in the modulation of several processes
related to a number of diseases where angiogenesis plays a key role in vascular homeostasis.
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Vascular and neuronal networks share many develop-
mental characteristics: both are ramified systems, have
similar tissue distribution patterns, and during develop-
ment, cellular precursors follow similar molecular cues.
Due to these similarities, researchers suggest that the for-
mation of both networks may be regulated by common
factors [1]. Additionally, vascular and neuronal pathways
share several guidance factors and receptors, which play a
non-canonical role to control the angiogenic process. Of
particular interest is the Netrin protein family, including
isoforms 1, 2, 3, and 4, which role has been well character-
ized in the nervous system [2]. More recently, these
proteins and receptors have been implicated in vascular
biology [3, 4]. However, since little is known about the
nature of Netrin-secreting cells, the putative endothelial
receptors mediating Netrin-driven angiogenesis and
especially due to the existence of conflicting reports,
researchers remain puzzled about the role of the
Netrin proteins in vascular development and patho-
logical conditions [2, 5].
Netrin-1, the most characterized ligand of the family,
is a critical axonal guidance protein [6] during embry-
onic development [7] and morphogenesis [8], and
recently has been related to angiogenic processes [9].
Netrins axonal functions have been linked to two classes
of receptors: (1) the deleted in colorectal cancer (DCC)
family, including DCC and its orthologue Neogenin-1,
and (2) the Unc5s family, including Unc5A through D.
Notably, Netrins can also bind to integrins, a large
family of transmembrane heterodimeric receptors that
comprise a broad set of functions, among them, joining
the actin cytoskeleton to extracellular matrix (ECM)
proteins [10]. Thus, Netrins acting on different
receptors lead to multifunctional effects through dif-
ferent signaling mechanisms, depending on the devel-
opmental stage and/or tissue involved. It has been
reported that Netrin-1 requires intracellular signaling
mechanism involving RhoA (member of the small
GTPase family), Fyn, focal adhesion kinase (FAK),
among others [11]. These mechanisms have been
shown in the context of cancer progression [12],
branching and membrane extension on oligodendro-
cyte [11], axon outgrowth in neurons [13], and osteo-
clast differentiation in bone [14]. While several
reports demonstrate that Netrin-1 is a key angiogenic
promoter, other researchers highlight its ability to
negatively regulate capillary branching in the devel-
oping vascular system and to reduce endothelial cell
migration in vitro [5, 15]. For example in the human
placenta, the most vascularized mammalian organ;
Netrins have different angiogenic implications ac-
cording to its localization and distribution pattern in
first trimester and term placentas [16, 17].Angiogenesis plays a key role during embryonic devel-
opment, but also is involved in postnatal wound-healing
processes. When a tissue is damaged, several events,
such as cell migration and proliferation, occur to recover
tissue integrity. These events involve extracellular matrix
deposition, angiogenesis, and tissue remodeling [18]. If
the recovering tissue is not properly vascularized, the
healing process can be impaired. Therefore, studying the
mechanisms that modulate angiogenesis is necessary for
the development of therapeutic tools in order to be able
to induce proper wound healing in affected patients.
In this context, researchers have demonstrated that
multipotent mesenchymal stromal cells (MSCs) not only
improve tissue repair in response to injury and dis-
ease, but also induce angiogenesis in damaged tissues
[19–21]. However, the molecular mechanisms under-
lying this beneficial effect are not fully understood. It
has been reported that MSCs do not differentiate at
wound locations; they have low grafting efficiency and
rather act by secreting a broad set of growth factors,
cytokines, chemokines, and bioactive lipids into the
wound microenvironment [22]. This suggests that MSCs
have a predominantly paracrine/autocrine signaling effect,
and are not particularly involved in lineage differentiation
[21, 23, 24]. We have recently demonstrated that MSCs
isolated from the stromal tissue of the umbilical cord,
named Wharton’s Jelly mesenchymal stem cells (WJ-
MSC) present enhanced angiogenic properties when com-
pared to MSCs isolated from adipose tissue (AD-MSC).
We showed that WJ-MSC promote angiogenic processes
via a paracrine mechanism, by expressing and secreting a
broad set of classic angiogenic factors, such as vascular
endothelial growth factor (VEGF), platelet-derived growth
factor AA (PDGF-AA), transforming growth factor beta 1
(TGF-β2), basic fibroblast growth factor 2 (bFGF), and
hepatocyte growth factor (HGF), which are directly and/
or indirectly linked with angiogenesis [19]. Our results
suggest that WJ-MSC are a primitive stromal cell popula-
tion, with therapeutic potential, due to the fact that they
expanded faster and to a greater extent than adult-derived
MSCs. However, the presence and secretion of other non-
canonical angiogenic molecules, such as Netrins, has not
yet been explored. Moreover, to our knowledge, there is
no description to date of how Netrin receptors present in
endothelial cells may modulate pro- and/or anti-
angiogenic effects of these ligands.
Accordingly, the aim of this work was to elucidate if
WJ-MSC-secreted Netrin-1 could exert an angiogenic role
both in vitro in primary cultures of human umbilical vein
endothelial cells (HUVEC) and in vivo in chicken embryo
chorioallantoic membrane (CAM assay). We here show
for the first time that Netrin-1, expressed and secreted by
WJ-MSC, acts as a non-canonical angiogenic factor.
Moreover, we show that integrin α6β1, Unc5b, and
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preferentially in regulating angiogenesis. Overall, our
results point to the dynamic balance between the pro- and
anti-angiogenic properties of Netrin-1 highlighting the
importance of the type and levels of Netrin-1 receptors
present locally in the final response. Still, there is a need
to further understand the mechanisms of action involved
in the observed angiogenic phenomenon. Undoubtedly,
these results have therapeutic potential in the develop-
ment and optimization of strategies aiming to manipulate
angiogenic processes for the treatment of a wide number
of pathologies.Methods
Isolation of human mesenchymal stem cells from
Wharton’s jelly of the umbilical cord (WJ-MSC)
Umbilical cords used for WJ-MSC isolation were
provided by Dr. Luis Tisné Brousse Hospital, Santiago,
Chile. Healthy pregnant women attending routine ante-
natal care at the maternity center offered to participate
voluntarily in this study. The inclusion criteria for se-
lected women were: non-smokers, normotensive, normal
cholesterol levels, not having pre-eclampsia, pregesta-
tional nor gestational diabetes mellitus, nor a family
history of premature vascular diseases, and no regular
consumption of medication. Written consent from these
patients was obtained. The ethics committee of the
University of Chile and Dr. Luis Tisné Brousse Hospital
approved this protocol.
Within 24 h umbilical cords were processed in our la-
boratory following standard procedures [19, 25]. Briefly,
the umbilical cord was dissected to discard blood
vessels, then was cut into 2-mm2 pieces and digested
with collagenase I (1 μg/μL, Gibco by Life Technologies,
Carlsbad, CA, USA) in phosphate-buffered saline (PBS,
pH 7.4) with gentle agitation at 37 °C for 16 h in order
to disaggregate the tissue. The cells obtained by subse-
quent centrifugation (2000 rpm, 10 min) were then
washed and seeded in Dulbecco’s modified Eagle’s
medium (DMEM) (Life Technologies) containing 10%
fetal bovine serum (FBS) (Hyclone, Logan, UT, USA)
with antibiotics (100 U/mL penicillin/streptomycin,
Thermo Fisher Scientific, Waltham, |MA, USA) and
maintained in this condition for 24 h at 37 °C, 5%
CO2. Afterwards, non-adherent cells were discarded
and adherent cells were incubated at 37 °C, 5% CO2,
changing the medium every 2–3 days. All primary cul-
tures of WJ-MSC were used between passages 2–5.
Human adipose tissue-derived mesenchymal stem cells
(AD-MSC) and human bone marrow-derived mesen-
chymal stem cells (BM-MSC), kindly donated by Dr.
Montencinos, were cultivated in the same conditions
as WJ-MSC.Human umbilical vein endothelial cells (HUVEC) isolation
and culture
HUVEC were obtained from full-term normal umbilical
cords as described [26]. Briefly, umbilical veins were
rinsed with warm (37 °C) phosphate-buffered saline
solution (PBS, in mM: NaCl 136, KCl 2.7, Na2HPO4 7.8,
KH2PO4 1.5, pH 7.4) and endothelial cells were
isolated by collagenase (0.2 mg/mL) digestion and
cultured (37 °C, 5% CO2) up to passage 2 in medium
199 (M199) supplemented with 10% newborn calf
serum, 10% fetal calf serum, 3.2 mM L-glutamine and
100 U/mL penicillin-streptomycin. The medium was
changed every 2 days until confluence was reached.
All primary cultures of HUVEC were used between
passages 2–5.
Conditioned media precipitation and Netrin-1
determination
In order to evaluate the secretion of Netrins by WJ-
MSC, conditioned media were collected after 48 h of
culture in serum starvation. To analyze the samples,
through Western blotting, we concentrated the proteins
secreted by the cultured cells. Briefly, conditioned media
was distributed in aliquots of 1 mL. Next, 500 μL of
methanol at −20 °C was added and vortexed for 30 s,
then 125 μL of chloroform was added following a final
vortex step of 20 s, medium was centrifuged at 14,000
rpm for 5 min. Finally, the interface was recovered, and
suspended in 25 μL of loading buffer. The pellets were
frozen at −20 °C until further use. The same sample of
conditioned media was used to evaluate Netrin-1 levels
secreted by WJ-MSC through ELISA (USCN Life Science
Inc., Houston, TX, USA).
Histological analysis and immunohistochemistry
Umbilical cords were recovered and fixed with 4%
paraformaldehyde for 8 h, dehydrated with graded alco-
hols (75–100%) and paraffin embedded. Next, 12-μm
sections underwent treatment with proteinase K for
antigen retrieval and were then treated with 3%
hydrogen peroxide in methanol to block endogenous
peroxidase activity. After washing twice with PBS,
sections were incubated with horse serum for 1 h and
then incubated for 1 h at 37 °C with anti-Netrin-1 or −4
(R&D Systems, Minneapolis, MN, USA). Next, sections
were washed twice with PBS before incubation with the
secondary antibody for 20 min at 37 °C. Then, the sec-
tions were incubated with ABC solution (Vectastain
ABC Kit, Vector Laboratories, Burlingame, CA, USA)
for 20 min at 37 °C, washed twice with PBS and the
reaction developed using DAB (Vector Laboratories).
Sections were stained in hematoxylin (Vector Laboratories)
and eosin Y (Sigma-Aldrich, St. Louis, MO, USA) and
mounted.
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WJ-MSC cultures from different donors were analyzed
by flow cytometry (FACSCanto II, BD Biosciences, San
Jose, CA, USA) in order to evaluate the presence of clas-
sical MSC markers using same conditions as previously
described [19]. In addition, we analyzed for Netrin-1 and
Netrin-4 and the CD29 non-classical receptor.
Confocal microscopy
WJ-MSC or HUVEC monolayers were grown on Lab-
Tek® chamber slides with cover (Nunc, Naperville, IL,
USA) up to 80% confluence, then rinsed in Hanks’ solu-
tion and fixed in 4% paraformaldehyde (15 min). Fixed
cells were rinsed with Hanks’ solution, permeabilized
with 0.1% Triton X-100 (20 min), and blocked (1 h) with
1% bovine serum albumin (BSA). Monolayers were
incubated for 30 min at 37 °C with combinations of the
following antibodies: Netrin-1 and −4 (R&D Systems),
Neogenin-1 and eNOS (Santa Cruz Biotechnology,
Dallas, TX, USA), UNC5b (Cell Signaling, Danvers, MA,
USA), CD29 (Thermo Fisher Scientific), VEGF (Abcam,
Cambridge, MA, USA) or CD31 (Sigma-Aldrich)
followed by incubation with the corresponding second-
ary antibodies (Alexa Fluor 488 and 555; Molecular
Probes, Eugene, OR, USA). Nuclei were stained with
4’, 6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich).
Fluorescent secondary antibodies were visualized with
Zeiss LSM 510 META (Carl Zeiss Microscopy GmbH.,
Jena, Germany).
RNA isolation and real-time polymerase chain reaction
(qPCR)
Total RNA was isolated using the Thermo Fisher Scien-
tific kit following manufacturer’s instructions. RNA qual-
ity and integrity were insured by gel visualization and
spectrophotometric analysis (OD260/280), quantified at
260 nm. Aliquots of 1 μg of total RNA were retro-
transcribed into cDNA using dNTPs (10 mM) plus Ran-
dom Primer (3 μg/μL) and RevertAid™ Reverse Tran-
scriptase 200 U/μL. qPCR experiments were performed
using 1 ng of cDNA as template, SYBR Green Mix and a
Stratagene Mx3000P real-time PCR system (Agilent
Technologies, Santa Clara, CA, USA). Primers were de-
signed for specific amplification of different receptors
and ligands (Additional file 1: Table S1). HotStart was
activated (15 min, 95 °C) and assays included a 95 °C de-
naturation (15 s), annealing (20 s) at 60 °C, and exten-
sion at 72 °C (10 s). Fluorescent products were detected
after an additional 3-second step to 5 °C below the prod-
uct melting temperature (Tm). Product specificity was
confirmed by agarose gel electrophoresis (2% v/v) and
melting curve analysis. Amplification analysis was carried
out with the MxPro software (Stratagene, San Diego,
CA, USA) and relative quantification was calculatedusing the ΔΔCT method. GAPDH was used as a
housekeeping gene, former confirmation that its ex-
pression levels did not change between experiments.
Tube formation assay
The tube formation assay was used as a model for as-
sessment of endothelial migration, a critical parameter
in angiogenesis. Matrigel (BD Matrigel; BD Biosciences)
was thawed overnight at 4 °C and administered by cold
tips in 50 μL per well in cold 96-well cell culture plates.
Matrigel made a thin gel layer after incubation at 37 °C
for 1 h. A total of 55,000 cells were seeded on each
Matrigel-coated well, and after 4 h network formation
was evaluated under a light microscope. Results repre-
sent experiments carried out in duplicate at least three
times. Matrigel experimental conditions included CBO
(a VEGF-receptor inhibitor, 20 μM, Calbiochem, San
Diego, CA, USA), IgG (an isotype antibody control, 2
μg/mL), 2F5 (a novel drug targeting Netrin-1, 2 μg/mL,
kindly provided by Dr. Mehlen), anti-Netrin-1 antibody
(R&D Systems, 2 μg/mL) and exoenzyme C3 transferase
(RhoA inhibitor, Cytoskeleton, Inc., Denver, CO, USA,
CT04 1–1.5 μg/mL), in absence or presence of recom-
binant human Netrin-1 (R&D Systems, 10 pg/mL–1000
ng/mL); all in endothelial basal media (EBM). In order
to inhibit basal secretion of VEGF and Netrin-1, HUVEC
were cultured 1 h with CBO, 2F5 or exoenzyme C3
transferase prior to each experiment and once after
Matrigel polymerization.
Wound-healing assay
HUVEC were used to study the paracrine effect of WJ-
MSC-conditioned media (48 h) and recombinant human
Netrin-1 (10–1000 ng/mL) on endothelial cell migration
potential through a wound-healing assay. Immediately
after scratching the confluent HUVEC monolayer using
200-μL sterile tips, wound healing was initiated by ad-
ministering recombinant human Netrin-1 (R&D Sys-
tems) in different wells of a 24-well plate. Photographs
were taken 8 and 24 h after wounding and area of
remaining scratched zone was measured.
Western blot
Primary cell cultures of HUVEC or WJ-MSC were har-
vested in monolayers or seeded in Integra® Matrix scaf-
fold (IM; Integra® LifeSciences Corp., Plainsbro, NJ,
USA) or a home-made collagen I (Col) solution obtained
from Sprague-Dawley rat tails, as previously described
[19]. Homogenates were suspended in SDS lysis buffer
with added protease and phosphatase inhibitors at 4 °C.
Equal amounts of protein were separated by 8–12%
SDS-PAGE, followed by Western blotting using anti-
Netrin-1 (66 kDa) and −4 (70–75 kDa) (R&D Systems),
anti-VEGF (43–45 kDa) and anti-UNC5c (103 kDa)
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ERM (index of activated RhoA/ROCK signaling) (75–80
kDa) (BD Transduction Laboratories), anti-UNC5b (130
kDa) (Cell Signaling), anti-Neogenin-1 (175 kDa) and
anti-RhoA (24 kDa) (Santa Cruz Biotechnology). The
monoclonal mouse anti-β actin (42 kDa) (Sigma-Aldrich)
antibody was used as loading control. Membranes
were washed in Tris-buffered saline (TBS) with 0.1%
Tween, and incubated (1 h, 22 °C) in TBS/0.1% Tween
containing horseradish peroxidase-conjugated goat
anti-rabbit, anti-sheep or anti-mouse secondary anti-
bodies. Bands were visualized using enhanced chemi-
luminescence (ECL; Amersham Biosciences, Little
Chalfont, UK).Chicken chorioallantoic membrane (CAM) assay
WJ-MSC (1.5*106) were used in CAM assays. The
experimental approaches included: DMEM (20 μL), 2F5
(0.5 μg/μL, kindly provided by Dr. Mehlen), CBO
(50 μM, Calbiochem), C3 transferase (Cytoskeleton, Inc.,
CT04 1–1.5 μg/mL) and recombinant human Netrin-1
(R&D Systems, 10 ng/mL). Fertilized chicken eggs (Rock
iso, Agricola Chorombo, Santiago, Chile) were incubated
at 38.5 °C with 75% RH. At embryonic day 3 (E3), eggs
were wiped with 70% ethanol and 3 mL of albumin were
extracted from each egg, after which eggs were returned
to the incubator. On E4, a window of 2 cm2 was opened
and pen/strep (250 μL, 100 U, 100 mg; Invitrogen) was
applied prior to returning to the incubator. On E7, a
plastic ring (6 mm in diameter and 2 mm in height) was
inserted and on E8, WJ-MSC (1.5*106) were placed over
the CAM, after which an initial image was obtained. An-
giogenic response was imaged every 24 h with a digital
camera HD IC80 (Leica, Wetzlar, Germany). DMEM
was used as negative control. We used the perimeter in-
side of the plastic ring, where the stimulus was applied
in the study area. In order to quantify the number of
branches of the blood vessels crossing this area, we used
the software Image J (NIH, Bethesda, MD, USA). In E12,
cream was added below the CAM before photographing
as previously described [19].Statistical analysis
All the determinations were carried out in triplicate.
Values are mean ± S.E.M., where n indicates number of in-
dependent cell cultures isolated from different umbilical
cords (n = 3–7). Comparisons between two and more
groups were performed by means of Student’s unpaired t
test and analysis of variance (ANOVA), respectively. If the
ANOVA demonstrated a significant interaction between
variables, post hoc analyses were performed by multiple-
comparison Bonferroni correction test. The software
Graphpad Prism 5.0b (GraphPad Software Inc., San Diego,CA, USA) was used for data analysis. p < 0.05 was consid-
ered statistically significant.
Results
WJ-MSC express and secrete non-classical angiogenic
factors
The expression of Netrins was first characterized in
Wharton’s jelly umbilical cord sections (Fig. 1a). We
detected preferentially the presence of Netrin-1 but not
of Netrin-4. These results were corroborated by qPCR
experiments (Additional file 1: Figure S1A) and con-
firmed by flow cytometry and immunofluorescence on
WJ-MSC cultures (Fig. 1b). Netrin-1 is highly expressed
throughout the early passages (Additional file 1: Figure
S1B) and can also be detected in AD-MSC and BM-
MSC (Additional file 1: Figure S1C). Furthermore, both
intracellular Netrin-1 production and secretion into
conditioned media could be detected, similar to VEGF,
used as a positive control. Nevertheless Netrin-4 was
not detected (Fig. 1c). We found that Netrin-1 secretion
by WJ-MSC measured by ELISA assay was in the 25–30
pg/mL range (Fig. 1d), similar to recently reported levels
in the umbilical cord blood [27]. In order to evaluate if
WJ-MSC produce Netrin-1 when confined in a three-
dimensional matrix more similar to their in vivo niche,
cells were seeded in two types of scaffolds: Integra®
matrix (IM) or collagen I (Col). We found that Netrin-1
synthesis after 24 h in both matrices was equally de-
tected in cell lysate. However, the Netrin-1 secretion
levels in the conditioned media were higher when cells
were seeded in IM compared to Col (Fig. 1e). This is
consistent with our previous results showing that WJ-
MSC improve their angiogenic capabilities on IM [19].
Netrin-1 promotes endothelial cell migration and
pro-angiogenic response
Having characterized the expression of canonical and
non-canonical angiogenic factors in WJ-MSC, we next
decided to study the ability of recombinant human
Netrin-1 to induce a pro-angiogenic response in primary
endothelial cells [17]. In particular, we evaluated cell mi-
gration in response to different Netrin-1 concentrations
using the wound-healing assay on HUVEC. As shown in
Fig. 2a, the wound area at 8 h decreased only at the
lowest ligand concentrations, i.e., 10 and 100 ng/mL of
Netrin-1, corresponding to the reported physiological
concentration range [3, 28]. It is noteworthy to mention
that Netrin-1 effect on HUVEC migration was similar to
VEGF, 59.6% vs. 60%, respectively (Fig. 2b). Indeed the
WJ-MSC secretome had pro-angiogenic potential as
verified by a wound-healing assay being equal to the
positive control VEGF in increasing the closure of a
wound in primary HUVEC cultures (Additional file 1:
Figure S2). As an alternative method to study the
Fig. 1 Netrin-1 is preferentially expressed and secreted by Wharton’s jelly-derived mesenchymal stem cells (WJ-MSC), whilst Netrin-4 expression is
almost absent. Netrin-1 (NTN-1) and Netrin-4 (NTN-4) expression was confirmed by different experimental techniques. a Representative images of
the histological analysis of umbilical cord sections are shown. MSCs uniformly distribute within Wharton’s jelly and show positive staining for
Alcian Blue and Netrins (magnification × 20). Inset show optical zoom images of NTN-1 and NTN-4 staining (n = 3). b Flow cytometry and
immunofluorescence anti-NTN-1 and −4 confirm preferential expression of NTN-1 in WJ-MSC (n = 3) (magnification × 63). c Western blot for
NTN-1, NTN-4 and vascular endothelial growth factor (VEGF) (positive control) in whole cell lysate (CL) and conditioned media (CM) of WJ-MSC
cultures. β-actin (for CL) and Ponceau (for CM) were used as internal loading controls, respectively (n = 3–7). d ELISA analysis for NTN-1 in
WJ-MSC; CM was obtained at indicated time points (n = 4). e Western blot for NTN-1 in WJ-MSC, seeded 24 h in Integra® matrix (IM) or collagen I
(Col), versus respective empty scaffold (−) used as negative control. Ligand expression was analyzed both in CL or CM. β-actin and Ponceau were
used as internal loading controls, respectively (n = 4–5)
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used the two-dimensional tubule formation assay in which
endothelial cells organize into tubular structures in re-
sponse to an angiogenic stimulus. We found that Netrin-1
promoted tube formation in a dose-dependent manner,
with low concentrations (10 ng/mL) having a greater
effect than higher doses (100–1000 ng/mL). The latter
indicates that at high doses Netrin-1 could lose its ability
of inducing endothelial cell migration and even prevent
endothelial cell movements (Fig. 2c–d). These results
are consistent with other studies that suggested a
pro-angiogenic role for Netrin-1 at physiological concen-
trations [3, 29, 30]. Hence, we studied the angiogenic
properties of lower dose-response curves of recombinant
human Netrin-1. Notably, the tubule formation and
branch points were promoted in a dose-dependent man-
ner even in the pg/mL range (Additional file 1: Figure S3).Endogenous Netrin-1, present in WJ-MSC-conditioned
medium, promotes tubule formation in endothelial cells
WJ-MSC-conditioned media proved to be angiogenic,
corroborating our former experiments [19]. We tested
the contribution of Netrin-1 present in the WJ-MSC-
conditioned media (48 h) by comparing the effect to re-
combinant human Netrin-1 (10 ng/mL), concentration
that induced the maximal physiological angiogenic
response, to the one elicited by VEGF. Consistent with
VEGF being an important mediator of this response, the
addition of a VEGF-receptor inhibitor (CBO, 20 μM)
[31] decreased its pro-angiogenic effect, as observed
even with VEGF co-treatment (40 ng/mL) (Additional
file 1: Figure S4). Next we treated WJ-MSC with VEGF-
receptor inhibitor (CBO, 20 μM), a drug targeting
Netrin-1 (2F5, 2 μg/mL) [32], a neutralizing Netrin-1
antibody (R&D Systems, 2 μg/mL) [33] and isotype
Fig. 2 Netrin-1 induces angiogenesis in vitro in HUVEC. a Netrin-1 (NTN-1) influence on HUVEC cell migration was determined using scratch assay,
where cells were serum-starved and treated for 8 h with different recombinant human NTN-1 concentrations, as indicated. Endothelial basal
media (EBM) was used as internal reference and recombinant human vascular endothelial growth factor (VEGF) (40 ng/mL) was used as a positive
control. Representative pictures of each condition are shown (amplification × 10). b Quantified results correspond to the mean ± S.E.M. (n = 3,
*p < 0.05). c The effect of recombinant human NTN-1 was determined in vitro to evaluate angiogenesis through tubule formation assay. HUVEC
were serum-starved and seeded on Matrigel and treated with increased concentrations of NTN-1 for 4 h. EBM alone was used as internal
reference and endothelial growth media (EGM) was used as a positive control. Representative images are shown for each experimental condition
(scale bar = 15 μm). d Quantified results correspond to the mean ± S.E.M. (n = 6, *p < 0.05)
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binant human Netrin-1 and IgG, as well as the internal
positive control-endothelial growth medium (EGM) pro-
moted an angiogenic effect on HUVEC when compared
to endothelial basal medium (EBM). On the other hand,
both 2F5 and neutralizing Netrin-1 antibody inhibited
significantly the pro-angiogenic responses on HUVEC
(Fig. 3a–b). Likewise, WJ-MSC-conditioned media (48 h)
and recombinant human Netrin-1 (10 ng/mL) increased
tubule formation and branch points. Nonetheless, 2F5
and CBO inhibited these pro-angiogenic responses in
each condition on HUVEC (Fig. 4a–b). Of note, when
excluding the VEGF contribution with the use of the
CBO inhibitor, we still could detect a pro-angiogenic
effect on HUVEC with WJ-MSC-conditioned media,
suggesting an important contribution of non-canonical
pro-angiogenic factors such as Netrin-1.
Netrin-1 induces angiogenesis in vivo in a CAM assay
Having evaluated the in vitro effect that Netrin-1 se-
creted by WJ-MSC exerts, we extended our observations
by assessing its contribution to the angiogenic response
on a chicken chorioallantoic membrane (CAM) assay
in vivo (Fig. 5a). We found that WJ-MSC inducedfunctional blood vessel formation compared to control
(DMEM), an effect that remained after 96 h of stimulus.
A different effect was observed when a Netrin-1-
targeting drug (2F5, 0.5 μg/μl) [32], or VEGF-receptor
inhibitor (CBO, 50 μM) [34] were placed on WJ-MSC
confined in the plastic ring, because both drugs de-
creased the blood vessel formation by approximately
50% (Fig. 5b). These results indicate that WJ-MSC
synthesize pro-angiogenic factors including not only
canonical ones [19] but also non-canonical such as
Netrin-1, fostering the growth of newly recruited endo-
thelial cells from the CAM.
Endothelial cells of the umbilical vein express low
amounts of the Netrin’s classical receptors Neogenin-1,
UNC5b and UNC5c, but not DCC
Even though Netrin-1 has been widely studied in endo-
thelial cells, discrepancies exist about which of the
receptors that bind Netrin-1 could be involved in the
angiogenic processes. Because HUVEC responded to
Netrin-1, we explored the possible candidate of classical
and non-classical receptors. In addition, we also ex-
plored the expression of Netrins by HUVEC itself
(Fig. 6a–d). We evaluated by qPCR expression of
Fig. 3 Netrin-1 promotes angiogenesis in HUVEC. a Representative images of HUVEC tubule assay. Cells were exposed for 4 h to endothelial basal
media (EBM), endothelial growth media (EGM), IgG (internal antibody control, 2 μg/mL), 2F5 [a drug targeting Netrin-1 (NTN-1), 2 μg/mL] and
anti-NTN-1 antibody (R&D Systems, 2 μg/mL), in absence or presence of recombinant human NTN-1 (10 ng/mL), scale bar = 15 μm. b Quantified
data correspond to the mean ± S.E.M. (n = 4, *p < 0.05 vs. EBM, γp < 0.05 vs. NTN-1, αp < 0.05 vs. IgG + NTN-1)
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Neogenin-1, DCC, UNC5b, and UNC5c protein expres-
sion was also assayed by Western blot. Of note, among
the classical receptors only Neogenin-1, UNC5b and
UNC5c were detectable in HUVEC. Furthermore, in line
with its recently described Netrin receptor function, in-
tegrin expression was also found, and further confirmed
by flow cytometry in HUVEC [8, 35]. Moreover, the en-
dogenous Netrins contribution in HUVEC, as assayed by
Western blot showed that these cells express actually
more Netrin-4 than Netrin-1, but both expression levels
remain lower than that of VEGF (Fig. 6b, d). In fact,
HUVEC-conditioned medium (48 h) did not have any
contribution in the angiogenic response observed
in vitro, ruling out an autocrine contribution (data not
shown).
Netrin-1 contribution to angiogenesis is not mediated by
endothelial RhoA/ROCK signaling
Netrin-1 and its receptors could regulate angiogenesis
by activating a variety of intracellular pathways [12].
Neogenin-1 and Unc5b are both moderately expressed
in HUVEC. Both receptors signal through RhoA/ROCKpathway activation [13]. Thus, in order to gain insight
into the molecular mechanism underlying Netrin-1
function in HUVEC, we evaluated if the RhoA/ROCK
pathway was involved in the angiogenic responses ob-
served in HUVEC. By using a highly potent reagent that
targets endogenous RhoA protein, exoenzyme C3 trans-
ferase, we evaluated the contribution of this signaling
cascade in Netrin-1-driven angiogenesis. We found that
both in vitro (Fig. 7a) and in vivo (Fig. 7b) RhoA/ROCK
modulates angiogenesis, since pharmacological inhib-
ition of the pathway using 1.5 μg/mL of exoenzyme C3
transferase disturbs tubule formation significantly. As
expected, this lower RhoA/ROCK activity was in accord-
ance with a decrease in ERM phosphorylation (Fig. 7c).
Yet using Netrin-1 in combination with exoenzyme C3
transferase did not diminish the Netrin-1 angiogenic
response, revealing that probably other downstream
signaling effectors are involved (Fig. 7a–b).
Discussion
Stem cell-based therapy plays an important role in the
treatment of various diseases. Many authors have shown
that MSCs have a significant effect on angiogenesis [36].
Fig. 4 Netrin-1, secreted by WJ-MSC, promotes angiogenesis in HUVEC. a Representative images of HUVEC tubule assay treated as indicated. Cells
were exposed for 4 h to DMEM, endothelial growth media (EGM), WJ-MSC-conditioned media (CM), 2F5 [a drug targeting Netrin-1 (NTN-1), 0.5
μg/μL] and CBO (a VEGF-receptor inhibitor, 20 μM), scale bar = 15 μm. b Quantified data correspond to the mean ± S.E.M. (n = 3, *p < 0.05 vs.
DMEM, βp < 0.05 vs. EGM, Φp < 0.05 vs. CM)
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bioartificial scaffolds could improve wound healing
in vitro and in vivo [19].
Previous studies have explored the possible role in em-
bryonic vasculogenesis and angiogenesis of a new group
of molecules. The Netrin protein family, which acts in
the nervous system in axonal guidance [3], has later
been found to be implicated in angiogenesis [37], cell
survival [38], and morphogenesis [39]. Moreover, recent
studies suggest that Netrin-1 may become a therapeutic
target in the treatment of various pathologies, either as a
stimulant or inhibitor of angiogenesis such as in diabetes
or cancer, respectively, even protecting the heart against
ischemia-reperfusion injury [2, 40, 41]. However, the
underlying cellular mechanisms and receptor specificity
characteristics involved in angiogenesis still require
further studies.
In the present study, we show for the first time that
Netrin-1 is produced and secreted by WJ-MSC through-
out different passages, and has the ability to stimulate
cell migration and motility in endothelial cells. We
present different approaches for the detection of the
non-canonical angiogenic factor, Netrin-1 in WJ-MSC.Using conditioned medium, as well as cell homogenates
from WJ-MSC cultures, our data show that this type of
cell is able to express and secrete Netrin-1 while Netrin-
4 is almost undetectable. Interestingly, Netrin-4 mRNA
is revealed in other MSC populations, presenting the
highest expression in BM-MSC [42]. Notably, our West-
ern blot analysis revealed that all assayed MSC sources
express Netrin-1 protein. So far, no evidence exists indi-
cating Netrin-1 expression in AD-MSC or BM-MSC.
However, Netrin-1, acting through its receptor UNC5b,
has been involved in osteoclast differentiation in the
bone marrow [43]. On the other hand, in obese adipose
tissue, the ligand recently has been implicated in
reduced migratory capacity of macrophages, increasing
its accumulation in adipose tissue [44]. Moreover,
Netrin-1 was informed to be highly expressed in obese
but not lean adipose tissue of humans and mice, acting
as a neuroimmune guidance cue via its receptor UNC5b.
The latter could explain our observation showing a
lower expression of Netrin-1 in AD-MSC in comparison
to BM-MSC. Nevertheless, at this point we cannot infer
that Netrin-1 is differentially expressed among AD-MSC
versus BM-MSC. Recently, in rodents, transplantation of
Fig. 5 Netrin-1 contributes to angiogenesis in vivo in a CAM assay. a Representative images of distinct experimental approaches on CAM: DMEM (20
μL), Wharton’s jelly-derived mesenchymal stem cells (WJ-MSC) (1.5*106), 2F5 [a drug targeting Netrin-1 (NTN-1), 0.5 μg/μL] and CBO (a VEGF-receptor
inhibitor, 50 μM), using for each condition approximately 15 eggs (scale bar = 1 mm). b Quantification of angiogenesis after 4 days of incubation in
experimental conditions as indicated. Data correspond to the mean ± S.E.M. (WJ-MSC, n = 5, *p < 0.05 vs. DMEM, Φp < 0.05 vs. WJ-MSC)
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to improve the function of the sciatic nerve after injury
[45] and also to exert a protective role after myocardial
infarction [46]. Given the reported beneficial impact of
Netrin-1 in tissue repair, the study of Netrin-1 and its
cognate receptors in these MSC populations warrant
further investigation.
Different researchers have studied the role of Netrin-1
in angiogenesis. Some of them demonstrating that it has
a positive, while others, showing a negative angiogenic
effect [5, 37]. Revealing its function is complex due to
the fact that the ligands are highly dependent on the
cellular context, the receptor through which they exert
their function, and their relative concentrations. We
therefore evaluated the effect of Netrin-1 on angiogen-
esis on HUVEC primary cultures only after confirmingits expression and secretion by WJ-MSC. We found that
Netrin-1 promoted migration and angiogenesis in vitro
in a dose-dependent manner, peaking around 50 ng/mL.
Moreover, Netrin-1 maintained its positive angiogenic
effect even when its dose was a thousand times lower
(pg/mL) than reported in many experimental setups.
These results agree with recent research that highlights
the pro-angiogenic role of Netrin-1 at low doses (10–
100 ng/mL) [3, 17, 29]. Our data are also in line with
research reporting an inhibitory effect of this ligand at
high doses (1 μg/mL) in angiogenesis, thus confirming
the potential dual role of Netrin-1 [15]. Some of the
reported inhibitory effects, although, were observed in
cells that are supplied either from single donors or from
pooled donor lines (commercially available HUVEC cell
lines) incubated in the presence of complete medium,
Fig. 6 Endothelial cells derived from human umbilical vein endothelial cells (HUVEC) express low levels of classic Netrin receptors and both
Netrin-1 (NTN-1) and Netrin-4 (NTN-4) ligands. a mRNA levels of classic (■) and non-classic (□) Netrin receptors were quantified by qPCR relative
to GAPDH expression (dashed line). Values are mean ± S.E.M. (n = 7). b Absence of DCC expression in HUVEC was established by Western blot,
while Neogenin-1 as well as UNC5b and UNC5c expression could be detected. Endogenous Netrins and vascular endothelial growth factor (VEGF)
expression in HUVEC was determined by Western blot. β-actin was used as internal reference (n = 5–7). c The non-classical Netrin receptor
integrin α3β1 was also detected by flow cytometry (n = 3). d Immunofluorescence for receptors and ligands in HUVEC (magnification × 63).
eNOS (endothelial nitric oxide synthase) or CD-31 (PECAM) were used as endothelial cell markers and DAPI for nuclear counterstain
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within the serum (data not shown, VP personal commu-
nication). It is therefore worth mentioning that our
study used exclusively HUVEC primary cultures from
single donors in serum-starved conditions.
Our results show that WJ-MSC produce and secrete
low amounts of Netrin-1 (25–30 pg/mL), similar to
those recently established in the umbilical cord blood
[27]. We found that the optimum pro-angiogenic effect
was between 10–100 ng/mL of recombinant Netrin-1,
which is within the admitted physiological range
reported to be between 50–150 ng/mL [5]. Our result is
therefore consistent with the hypothesis that Netrin-1
stimulates endothelial cell migration in vitro at low con-
centrations while conversely, at higher concentrations
tends to promote endothelial cell migration to a lesser
extent. This dose-dependency is termed a biphasic “bell-
shaped” dose-response curve [5, 37]. Clearly, to reveal
this bifunctional mode of action of Netrin-1 a more
comprehensive in vivo investigation is required.We were also interested in evaluating Netrin-1’s
specific contribution to angiogenesis by inhibiting its
function. Seeding HUVEC on Matrigel in presence of a
drug targeting Netrin-1, 2F5, or antibody-mediated
blockade of Netrin-1 [32, 33] suggests that Netrin-1
signaling pathway directs approximately 70% of the
angiogenic process. These results are in accordance with
other reports that show the same effect using other
experimental approaches [7, 47, 48]. We can therefore
irrefutably conclude that this ligand is involved in endo-
thelial angiogenesis [7, 17].
Netrin-1 and its numerous receptors regulate different
cellular responses by activating a variety of intracellular
pathways. In a first attempt to elucidate the underlying
signaling mechanisms we focused on Netrin receptor
expression in HUVEC. Examining the Netrin’s classical
and non-classical receptor repertoire, we found that
HUVEC expressed low amounts of Neogenin-1. HUVEC
did not express the Neogenin-1 homologue, DCC. The
absence of DCC expression in HUVEC has been well
Fig. 7 RhoA/ROCK pathway contributes to angiogenesis in vitro and in vivo in a Netrin-1-independent manner. a Representative images of HUVEC
tubule assay. Cells were exposed for 4 h to endothelial basal media (EBM), endothelial growth media (EGM) and exoenzyme C3 transferase
(Cytoskeleton, Inc., 1–1.5 μg/mL), in absence or presence of recombinant human Netrin-1 (NTN-1) (10 ng/mL). The graphs shown below represent
quantified data corresponding to the mean ± S.E.M. [n = 3, *p < 0.05 vs. NTN-1, γp < 0.05 vs. C3 + NTN-1], scale bar = 15 μm. b Representative images
of distinct experimental approaches on CAM: PBS (20 μL), NTN-1, 10 ng/mL) and exoenzyme C3 transferase (Cytoskeleton, Inc., 1–1.5 μg/mL) (scale
bar = 1 mm). The graph represents quantification of angiogenesis after 4 days of incubation in experimental conditions as indicated. Data correspond
to the mean ± S.E.M. (n = 4, *p < 0.05 vs. NTN-1, γp < 0.05 vs. C3 + NTN-1). c Western blot for RhoA, phospho-ezrin-radixin-moesin (P-ERM, index of
activated RhoA/ROCK signaling) and β-actin in primary culture of HUVEC (n = 1) in absence (−) or presence (+) of exoenzyme C3 transferase
(Cytoskeleton, Inc., 1.5 μg/mL)
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controversy exists regarding the expression of Neogenin-
1 in HUVEC. Many studies investigated Neogenin-1
only measuring mRNA levels and protein expression
compared to other tissues, mainly to brain tissue that re-
veals much higher Neogenin-1 levels. Based on these
comparisons, researchers conclude that Neogenin-1 is
almost undetectable or not present in HUVEC [40, 49].
Nevertherless, our ongoing research suggests that the
expression of Neogenin-1 could be of functional rele-
vance (VP, personal communication). Our present find-
ings demonstrate for the first time in primary cell
culture of HUVEC that members of the UNC5 family,
described as dependence receptors for Netrin-1 [38] are
expressed. UNC5 receptors facilitate repulsion andtherefore mediate the anti-angiogenic effect in endothe-
lial cells [15, 37]. Nevertheless, recent studies have pro-
posed that uncharacterized receptors located in
endothelium have an opposite role to UNC5b in cell mi-
gration, which is dependent on dose/concentration of
Netrin-1. The later leaves open the possibility that dur-
ing a disease progression, levels of Netrin-1 might be
modulated determining the severity of the disease [2].
We also found expression of integrin α6β1, a member
of a large family of transmembrane proteins, which
could be considered a non-classical receptor in HUVEC.
However, this type of integrin has been defined as
Netrin-4 receptor in lymphatic endothelium [50]. Due to
the fact that HUVEC express Netrin-4, it is possible that
α6βl may interact with this ligand in the fetal
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angiogenic role. Considering that umbilical cord remains
in continuity with placenta, this idea is feasible since
recently a group described that Netrin-4 inhibits cell
proliferation and angiogenesis in placenta [51].
Following the downstream pathway of Netrin-1, we
evaluated the RhoA/ROCK contribution to Netrin-1
receptor activation in endothelial cells. Several reports
have implicated RhoA/ROCK downstream signaling in
response to Netrin-1 in neuronal migration [13]. Yet
here we demonstrate that Netrin-1 can exert control of
angiogenesis in an independent manner of RhoA/ROCK.
Of note, we cannot rule out that at higher concentra-
tions of exoenzyme C3 transferase, Netrin-1 might com-
mand through Rho/ROCK signaling. In fact, the later
could be of importance given that Rho is not required
for capillary tube formation [52]. However, in this study
they used a C3 transferase recombinant (3 μg/mL) for at
least 18 h on commercially available HUVEC cell lines.
It is noteworthy that we cannot discard Netrin-1 down-
stream signaling with other proteins including Fyn, FAK,
among others [11–14].
To highlight the diversity of Netrin receptors that have
been examined, a new receptor CD146 for Netrin-1 in
endothelial cells was recently found to promote angiogen-
esis [48]. CD146, also known as melanoma cell adhesion
molecule (MCAM), member of the immunoglobulin (Ig)
superfamily, cooperates in different biological processes
including tumor metastasis, lymphocyte activation, and
morphogenesis during development, and tissue regener-
ation. Thus, CD146 plays a critical role in cell prolifera-
tion, migration, and tube formation in endothelial cells.
Tu and colleagues elegantly demonstrated an interaction
between CD146 and Netrin-1. Nevertheless, here we show
that HUVEC express low levels of Netrin-1 compared
with Netrin-4. We speculate that Netrin-1’s pro-
angiogenic contribution rather comes from an adjacent
cell present in the stroma, like WJ-MSC, which secrete
more Netrin-1 than Netrin-4. Moreover, vascular endo-
thelial cells are in direct contact with blood in the umbil-
ical cord [27]. Hence, it is possible that HUVEC produce
more Netrin-4 with anti-angiogenic effect to counteract
the Netrin-1 secreted by WJ-MSC. This homeostasis
could be imbalanced when the placenta vasculature
undergoes dramatic blood vessel remodeling, as in patho-
logical conditions related to pregnancy like IUGR, where
Netrin-4 was found with higher expression than Netrin-1.
Interestingly, coupled to this disease a derangement of
placental vessel formation has been described [27]. It is
worth pointing out that diverse researchers have described
that placenta can present structural and functional
alterations in macrovasculature and microvasculature
endothelium and have shown differential response to
locally released molecules [53]. Although these effectshave been mainly attributed to the expression of classical
angiogenic factors such as VEGF or FGF-2 by these cells,
our results suggest that the influence of other less studied
factors such as Netrin-1 cannot be ruled out. Collectively,
our research demonstrates that WJ-MSC produce not
only classical angiogenic factors such as VEGF, FGF-2 and
EGF [54], but also Netrin-1 as pro-angiogenic regulators
of HUVEC. Our results may have implications in the
modulation of several pathological conditions related with
placental angiogenesis dysfunction.
Conclusions
Here we demonstrate that WJ-MSC-conditioned medium
promotes angiogenesis and that this effect is partially me-
diated by Netrin-1 and independent of the RhoA/ROCK
signaling pathway. This result reveals vital information for
clinical approaches aimed at stimulating angiogenic
processes. Further in-depth studies to elucidate Netrin-1
mechanism of action will shed light on the development
of targeted therapies aiming to restore the physiological
balance between Netrin-1, other proteins in the Netrin
family and their receptors, for the desired therapeutic
effect.
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